Indeed, the results of recent analysis of postmortem brain samples from PD patients treated with AAV2-NRTN show that upon the injection to the putamen NRTN immunoreactivity can be detected only in a portion of the putamen [24]. Here, NRTN is linked to Parkinson disease.